Peptide-Drug Conjugation Service

Overview

Peptide-drug conjugates (PDCs) combine the targeting capabilities of peptides with the pharmacological properties of small molecule drugs, offering novel solutions for the treatment of various diseases. Our company is committed to providing you with quality peptide-drug conjugation service by leveraging our extensive expertise, cutting-edge technologies, and strict quality control measures.

Understanding PDCs

Peptide-drug conjugation involves the covalent attachment of peptides to pharmacologically active compounds, such as cytotoxic drugs and imaging agents. This conjugation can be achieved through various chemical linkers or bioconjugation techniques. By capitalizing on the target specificity of peptides and the therapeutic potency of drugs, PDCs have the potential to deliver drugs more precisely to their intended targets, reducing side effects and improving therapeutic efficacy.

Figure 1. A schematic of a peptide-drug conjugate structure, consisting of a target peptide,
linker, and drug, with different payloads ^[1].

Applications of PDCs

Targeted Cancer Therapy

One of the most promising application areas for PDCs is targeted cancer therapy. Peptides with high affinity for tumor-specific receptors or antigens can be conjugated to cytotoxic drugs, thereby selectively delivering therapeutic payloads to cancer cells. This targeted approach minimizes systemic toxicity and improves the therapeutic index of anticancer agents, thereby improving patient outcomes and reducing side effects.

Imaging and Diagnostics

Peptides with high affinity for disease-specific biomarkers can be conjugated to imaging agents, such as fluorophores or radionuclides, to enable non-invasive visualization and detection of pathological tissues. This helps to enable early disease detection as well as therapeutic response monitoring, thereby facilitating personalized medicine and precision diagnosis.

Enhanced Drug Delivery

In addition to targeted therapies and diagnostics, PDCs offer opportunities for enhanced drug delivery and tissue penetration. Peptides can act as carrier molecules to facilitate the passage of therapeutic agents through biological barriers (e.g., blood-brain barrier or cell membranes). By conjugating drugs with cell-penetrating peptides or tissue-targeting peptides, researchers can improve drug bioavailability, distribution, and efficacy, overcoming limitations associated with poor solubility or systemic clearance.

PDCs vs. ADCs

Peptide-drug conjugates (PDCs) and antibody-drug conjugates (ADCs) are both innovative solutions in drug delivery, enabling targeted delivery of therapeutic agents to specific cells or tissues. However, PDCs have obvious advantages in terms of size, tumor targeting, internalization kinetics, immunogenicity, manufacturing complexity, chemical stability, and versatility of drug payloads. These advantages make PDCs a promising candidate for the development of next-generation targeted therapeutic drugs with higher efficacy and safety. The table below provides a detailed comparison of PDCs and ADCs.

Table 1. Comparison table of PDCs and ADCs

What We Offer

Our company has a highly sensitive instrument platform and rich experience in PDC analytical method development, which can quickly and efficiently solve the thorny problems encountered in PDC method development. We have built a peptide-drug conjugation service platform, which is committed to providing customers with research and development services for innovative peptide drugs, new peptide formulations and peptide generic drugs. If you are interested in our services, please feel free to contact us.